Compare Summit Therapeutics Inc (SMMT) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Taskus Inc — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Summit Therapeutics Inc is far larger — about 19× Taskus Inc's market cap, and Taskus Inc is more actively traded (201,303 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Taskus Inc for 34 Days on average.
| SMMT | TASK | |
|---|---|---|
Market Cap | $13.71B | $723.41M |
Volume | 6,173,057 | 201,303 |
Sector | Health | Technology |
52-Week High | $26.38 | $14.69 |
52-Week Low | $12.43 | $4.57 |
Typical Hold Time | 16 Days | 34 Days |
Enterprise Value | $13.04B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
TaskUs trades at $7.89, down 0.88% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin of 8.75%. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected. Analyst consensus is bullish with 55% buy ratings and $9.33 price target, representing 18% upside potential.
The stock presents value opportunity with solid profitability and AI services growth offsetting Trust & Safety declines. Key risks include labor cost pressures and client concentration. Positive cash flow generation and institutional accumulation support the bullish case, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
